Unjoni Ewropea - Malti - EMA (European Medicines Agency)

pfizer europe ma eeig - zoledronic acid monohydrate - iperkalċemija - drogi għat-trattament ta 'mard tal-għadam - 4 mg / 5 ml u 4 mg / 100 ml:il-prevenzjoni ta ' episodji relatati ma (ksur patoloġiku, kompressjoni tas-sinsla, radjazzjoni jew kirurġija fl-għadam, jew l-iperkalċemja kkawżata minn tumur) f'pazjenti adulti b'kanċer avvanzat li jinvolvi l-għadam. it-trattament ta ' pazjenti adulti b'iperkalċemja kkawżata minn tumur (tih). 5 mg / 100 ml: - trattament tal-osteoporożi:fl-nisa wara l-menopawsa;fl-irġiel;f'riskju akbar ta ' ksur, inklużi dawk bi trawma-ksur fil-ġenbejn. trattament ta ' osteoporożi assoċjat ma sistemiku fit-tul terapija bi glukokortikojdi:fl-nisa wara l-menopawsa;fl-irġiel;f'riskju miżjud ta'ksur. it-trattament tal-marda ta'paget ta ' l-għadam fl-adulti.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

teva b.v. - zoledronic acid - fractures, bone; cancer - drogi għat-trattament ta 'mard tal-għadam - prevenzjoni ta 'avvenimenti relatati mal-iskeletru u trattament ta' iperkalċemija kkawżata minn tumur.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

kyowa kirin holdings b.v. - burosumab - hypophosphatemia, familial; hypophosphatemic rickets, x-linked dominant; osteomalacia - drogi għat-trattament ta 'mard tal-għadam - crysvita is indicated for the treatment of x-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. crysvita is indicated for the treatment of fgf23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

mylan ire healthcare limited - pretomanid - tuberkulożi, b'resistema multidrug - antimikobatterjali - dovprela is indicated in combination with bedaquiline and linezolid, in adults, for the treatment of pulmonary extensively drug resistant (xdr), or treatment-intolerant or nonresponsive multidrug-resistant (mdr) tuberculosis (tb). għandha tingħata kunsiderazzjoni għall-gwida uffiċjali dwar l-użu xieraq ta ' sustanzi antibatteriċi.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

eurogenerics holdings b.v. - teriparatide - l-osteoporożi - homeostasi tal-kalċju - qutavina is indicated in adults. trattament ta 'l-osteoporożi f'nisa wara l-menopawża u fl-irġiel b'riskju akbar ta' ksur. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated. trattament ta 'osteoporożi assoċjat ma sostnut sistemika terapija bi glukokortikojdi f'nisa u l-irġiel f'riskju akbar ta' ksur.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

theramex ireland limited - teriparatide - l-osteoporożi - homeostasi tal-kalċju - livogiva is indicated in adults. trattament ta 'l-osteoporożi f'nisa wara l-menopawża u fl-irġiel b'riskju akbar ta' ksur. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated. trattament ta 'osteoporożi assoċjat ma sostnut sistemika terapija bi glukokortikojdi f'nisa u l-irġiel f'riskju akbar ta' ksur.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

accord healthcare s.l.u. - teriparatide - l-osteoporożi - homeostasi tal-kalċju - sondelbay is indicated in adults. trattament ta 'l-osteoporożi f'nisa wara l-menopawża u fl-irġiel b'riskju akbar ta' ksur. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated. trattament ta 'osteoporożi assoċjat ma sostnut sistemika terapija bi glukokortikojdi f'nisa u l-irġiel f'riskju akbar ta' ksur.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - teriparatide - osteoporosis; osteoporosis, postmenopausal - homeostasi tal-kalċju - teriparatide sun is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

strides pharma (cyprus) limited - teriparatide - osteoporosis; osteoporosis, postmenopausal - homeostasi tal-kalċju - kauliv is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

stemline therapeutics b.v. - elacestrant - neoplażmi tas-sider - terapija endokrinali - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.